BRVE starts Phase 3 for BHB-1893; cash funds into 2029
BRVE initiated Phase 3 trials for BHB-1893 in oHCM and nHCM. Cash reserves of $527.3 million post-IPO are expected to fund operations into 2029. Q2 2026 net loss widened to $18.6 million.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.